Recent Updates
Recently added Catalysts
SIBN Positive Sentiment

SI-BONE To Report First Quarter 2024 Financial Results on May 6, 2024

Key Takeaway: SI-BONE, Inc. announced it will report its financial results for the first quarter of 2024 on May 6, 2024. The report will be released after market close, followed by a conference call scheduled for 1:30 PM Pacific Time. Investors can access the live audio webcast through the company's website. SI-BONE continues to lead in technologies for minimally invasive surgical treatment of musculoskeletal disorders.
Price reaction · baseline $14.97 (2024-04-12 close) · clean, no other SIBN news in the window
day 0 close · peak
+2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Scheduled reporting of first quarter 2024 financial results indicates transparency.
  • Company has supported over 3,600 surgeons, demonstrating trust in its technology.
  • SI-BONE has a substantial body of clinical evidence backing its products.

Full Press Release Details

SANTA CLARA, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy today announced it will report financial results for the first quarter of 2024 after market close on Monday, May 6, 2024. Management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/xs5x4tbm. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.
SI-BONE (NASDAQ: SIBN) is a global leader in technology for surgical treatment of musculoskeletal disorders of the sacropelvic anatomy. Since pioneering minimally invasive surgery of the SI joint in 2009, SI-BONE has supported over 3,600 surgeons in performing a total of more than 95,000 sacropelvic procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies, including two randomized controlled trials and over 125 peer reviewed publications. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, spinopelvic fixation, and pelvic trauma.
For additional information on the company or the products including risks and benefits, please visit www.si-bone.com.

Frequently Asked Questions

When will SI-BONE report its Q1 2024 financial results?

SI-BONE will report Q1 2024 financial results on May 6, 2024.

How can I listen to SI-BONE's conference call?

Investors can listen by registering at the provided link or via the company website.

What is SI-BONE known for?

SI-BONE is recognized for its surgical treatments for sacropelvic musculoskeletal disorders.

How many sacropelvic procedures has SI-BONE supported?

SI-BONE has supported over 95,000 sacropelvic procedures globally.

Where can I find more information about SI-BONE's products?

More information about SI-BONE’s products is available on their official website.

Last updated: Apr 15, 2024